• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TAMOXIFEN Drug Record

  • Summary
  • Interactions
  • Claims
  • TAMOXIFEN chembl:CHEMBL83 ApprovedAntineoplastic

    Alternate Names:

    ICI-47699
    ICI-46474
    SOLTAMOX
    NOLVADEX
    TAMOXIFEN
    TAMOXIFÈNE
    1-P-BETA-DIMETHYLAMINOETHOXYPHENYL-TRANS-1,2-DIPHENYLBUT-1-ENE
    TRANS-TAMOXIFEN
    1-PARA-BETA-DIMETHYLAMINOETHOXYPHENYL-TRANS-1,2-DIPHENYLBUT-1-ENE
    (Z)-2-(4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY)-N,N-DIMETHYLETHANAMINE
    TAMOXIFENO
    (Z)-2-(PARA-(1,2-DIPHENYL-1-BUTENYL)PHENOXY)-N,N-DIMETHYLAMINE
    TAMOXIFENUM
    NOLVADEX®
    SOLTAMOX®
    ZD6157
    TAMOXIFENE
    drugbank:00675
    rxcui:10324
    chembl:CHEMBL83
    chemidplus:10540-29-1
    pubchem.compound:2733526

    Drug Info:

    Drug Class antineoplastic agents, hormonal
    Year of Approval 1977
    FDA Approval 1977
    Drug Class small molecule
    Drug Indications Antineoplastic Agents, Hormonal
    (8 More Sources)

    Publications:

    Scott SA et al., 2009, Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness., Nat Chem Biol
    Mc Ilroy et al., 2006, Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence., Endocr. Relat. Cancer
    Girault et al., 2006, Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer., Maturitas
    Hayes et al., 2010, Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results., Clin. Pharmacol. Ther.
    Sasson, 1991, Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor., Pathol. Biol.
    Chen et al., 2005, Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex., Int. J. Oncol.
    Gruvberger-Saal et al., 2007, Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma., Clin. Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Horner-Glister et al., 2005, Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells., J. Mol. Endocrinol.
    Ntukidem NI et al., 2008, Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen., Clin Pharmacol Ther
    Jain D et al., 2010, A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements., Bioorg Med Chem Lett
    Sridar C et al., 2012, Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein., Drug Metab Dispos
    Robinson et al., 2013, Activating ESR1 mutations in hormone-resistant metastatic breast cancer., Nat. Genet.
    Jeselsohn et al., 2014, Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer., Clin. Cancer Res.
    Toy et al., 2013, ESR1 ligand-binding domain mutations in hormone-resistant breast cancer., Nat. Genet.
    Ogawa T et al., 2006, m-Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators., Bioorg Med Chem Lett
    Rivera-Guevara C et al., 2010, Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha., Bioorg Med Chem
    Cyrus et al., 2010, Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs., ChemMedChem
    Fabian et al., Chemoprevention for high-risk women: tamoxifen and beyond., Breast J
    Osborne et al., 2003, Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer., J. Natl. Cancer Inst.
    Ribas et al., 2015, AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo., Mol. Cancer Ther.
    Stendahl et al., 2004, Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients., Br. J. Cancer
    Christov et al., 2003, Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors., Breast Cancer Res. Treat.
    Han et al., Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer., Oncol. Rep.
    Bhattacharyya et al., 1994, Protooncogene, growth factor, growth factor receptor, and estrogen and progesterone receptor gene expression in the immature rat uterus after treatment with estrogen and tamoxifen., J. Submicrosc. Cytol. Pathol.
    Narod SA et al., 2000, Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group., Lancet
    Pierce LJ et al., 2006, Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer., J Clin Oncol
    Gronwald J et al., 2006, Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update., Int J Cancer
    Metcalfe K et al., 2004, Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers., J Clin Oncol
    Jones et al., 2005, Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer., Oncogene
    Toimela et al., 1995, Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine., Ophthalmic Res.
    Suzuki et al., Effects of tamoxifen on mammary tumors and bone in 7,12-dimethylbenz-(a)anthracene-treated rats., Anticancer Res.
    Vadlamudi et al., 1998, Role of female sex steroids in regulating cholesteryl ester transfer protein in transgenic mice., Metab. Clin. Exp.
    Yamashita et al., 1993, Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells., Cancer Res.
    Klein DJ et al., 2013, PharmGKB summary: tamoxifen pathway, pharmacokinetics., Pharmacogenet Genomics
    Weng L et al., 2013, Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation., Ann Oncol
    Berns et al., 2000, Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer., Cancer Res.
    Kretschmer XC et al., 2005, CAR and PXR: xenosensors of endocrine disrupters?, Chem Biol Interact
    Harmsen et al., 2009, Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor., Cancer Chemother. Pharmacol.
    Nilsson et al., 2006, Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo., Cancer Res.
    Yu et al., 1994, Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines., Breast Cancer Res. Treat.
    Rokavec M et al., 2008, A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer., Cancer Res
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Ingle JN et al., 2013, Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention., Cancer Discov
    Eisen et al., 2002, Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells., Mol. Pharmacol.
    Gao T et al., 2014, CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance., PLoS One
    Grenman et al., 1987, In vitro effects of tamoxifen on UM-SCC head and neck cancer cell lines: correlation with the estrogen and progesterone receptor content., Int. J. Cancer
    Osborne et al., 1997, Minor products of reaction of DNA with alpha-acetoxytamoxifen., Carcinogenesis
    Kiyotani K et al., 2012, A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese., Hum Mol Genet
    Liu et al., 2007, Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells., Int. J. Cancer
    Raspollini et al., 2005, HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy., Pathol. Res. Pract.
    Kurokawa et al., 2001, Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer., Clin. Cancer Res.
    Levine et al., 1985, Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line., Cancer Res.
    Yager et al., 1986, Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats., Carcinogenesis
    Kimura et al., 2008, Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy., Hum. Mol. Genet.
    Ciocca et al., 1998, Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study)., Clin. Cancer Res.
    Chiarenza et al., 2001, Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7., Cancer Res.
    Duggan C et al., 2003, Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer., J Clin Oncol
    Abramson N et al., 2006, Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial., J Natl Cancer Inst
    Hartmaier RJ et al., 2012, A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone., Mol Endocrinol
    Liel et al., 1992, Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8)., Endocrinology
    Marttunen et al., 1998, Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients., J. Clin. Endocrinol. Metab.
    May et al., 2015, TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer., Endocr. Relat. Cancer
    Hofstra et al., Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer., Anticancer Res.
    Dejardin et al., 1991, Stimulatory effect of oestradiol-17 beta and tamoxifen on gross cystic disease fluid protein 15,000 production and mRNA levels in T47D human breast cancer cells., J. Mol. Endocrinol.
    Akinmade et al., 2008, Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells., Br. J. Cancer
    Robertson et al., 1998, Tamoxifen up-regulates oestrogen receptor-alpha, c-fos and glyceraldehyde 3-phosphate-dehydrogenase mRNAs in ovine endometrium., J. Steroid Biochem. Mol. Biol.
    Zheng et al., 2014, Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer., Oncogene
  • TAMOXIFEN   PIP

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1930624


    Sources:
    NCI

  • TAMOXIFEN   LRMDA

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22180457


    Sources:
    PharmGKB

  • TAMOXIFEN   RRAS2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19047159


    Sources:
    PharmGKB

  • TAMOXIFEN   E2F7

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23508821


    Sources:
    PharmGKB

  • TAMOXIFEN   PLD1

    Interaction Score: 1.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12237338 19136975


    Sources:
    DTC NCI

  • TAMOXIFEN   TFF3

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25900183


    Sources:
    CIViC

  • TAMOXIFEN   ZNF423

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23764426


    Sources:
    PharmGKB

  • TAMOXIFEN   PLD2

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19136975


    Sources:
    DTC

  • TAMOXIFEN   FMO1

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23962908


    Sources:
    PharmGKB

  • TAMOXIFEN   NCOA1

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22174377


    Sources:
    PharmGKB

  • TAMOXIFEN   F5

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14512389 16818854


    Sources:
    PharmGKB FDA

  • TAMOXIFEN   CCNA2

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24622579


    Sources:
    PharmGKB

  • TAMOXIFEN   MUC16

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10629663


    Sources:
    NCI

  • TAMOXIFEN   COL18A1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16651433


    Sources:
    NCI

  • TAMOXIFEN   FMO3

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23962908


    Sources:
    PharmGKB

  • TAMOXIFEN   CCND1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15138475 12602925 12469160


    Sources:
    NCI CIViC

  • TAMOXIFEN   ESR2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17158759 16822624 20827267 2011412 16010412 17404078 11752352 16326830 17713466 20659801


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB

  • TAMOXIFEN   HSPB2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9607585


    Sources:
    NCI

  • TAMOXIFEN   MYOD1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18511457


    Sources:
    NCI

  • TAMOXIFEN   HEXB

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8577454


    Sources:
    NCI

  • TAMOXIFEN   NCOA3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12618500


    Sources:
    NCI

  • TAMOXIFEN   EDN1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8425178


    Sources:
    NCI

  • TAMOXIFEN   CETP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9751231


    Sources:
    NCI

  • TAMOXIFEN   GAPDH

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9883985


    Sources:
    NCI

  • TAMOXIFEN   DHFR

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3978632


    Sources:
    NCI

  • TAMOXIFEN   GGT1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2877750


    Sources:
    NCI

  • TAMOXIFEN   KLK3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7532467


    Sources:
    NCI

  • TAMOXIFEN   ESR1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    24185510 24398047 24185512 16735120 20659801 20621492 2011412 20512796 11906441 11752352 17713466


    Sources:
    DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial TEND CIViC PharmGKB TTD FDA

  • TAMOXIFEN   PGR

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3793272


    Sources:
    ClearityFoundationBiomarkers NCI PharmGKB FDA

  • TAMOXIFEN   TGM2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9067554


    Sources:
    NCI

  • TAMOXIFEN   BGLAP

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9543133


    Sources:
    NCI

  • TAMOXIFEN   NRG1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18283314


    Sources:
    NCI

  • TAMOXIFEN   BRCA1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11130383 16636335 16331614 15197194 15750629


    Sources:
    NCI PharmGKB

  • TAMOXIFEN   F2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • TAMOXIFEN   TYMS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9615734


    Sources:
    NCI

  • TAMOXIFEN   TGFB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8019941


    Sources:
    NCI

  • TAMOXIFEN   AURKA

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24166501


    Sources:
    CIViC

  • TAMOXIFEN   CYP2B6

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22942317


    Sources:
    DTC

  • TAMOXIFEN   NTRK1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11306479


    Sources:
    NCI

  • TAMOXIFEN   CYP19A1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TAMOXIFEN   ERBB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17266042 15901136 11916237


    Sources:
    NCI

  • TAMOXIFEN   NR1I2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16054614 18839173


    Sources:
    PharmGKB

  • TAMOXIFEN   ABCC2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TAMOXIFEN   PIK3CA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD5363 + Tamoxifen
    Indication/Tumor Type estrogen-receptor positive breast cancer
    Response Type predicted – sensitive

    PMIDs:
    26116361


    Sources:
    JAX-CKB

  • TAMOXIFEN   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10786679


    Sources:
    DTC CIViC

  • TAMOXIFEN   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 23962908


    Sources:
    DTC PharmGKB

  • TAMOXIFEN   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAMOXIFEN   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TAMOXIFEN   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1315250


    Sources:
    NCI

  • TAMOXIFEN   ABCB1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TAMOXIFEN   ATXN2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAMOXIFEN   BAZ2B

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAMOXIFEN   IDH1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAMOXIFEN   KDM4A

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAMOXIFEN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TAMOXIFEN   GMNN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAMOXIFEN   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • TAMOXIFEN   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: TAMOXIFEN

    • Version: 01-August-2011

    Alternate Names:
    TAMOXIFEN Primary Drug Name

    Drug Info:
    Year of Approval 1977
    Drug Class antineoplastic agents, hormonal

    Publications:

  • TdgClinicalTrial: TAMOXIFEN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents, Hormonal
    Drug Class small molecule
    FDA Approval 1977

    Publications:

  • NCI: TAMOXIFEN

    • Version: 14-September-2017

    Alternate Names:
    C855 NCI drug code

    Drug Info:

    Publications:
    Eisen et al., 2002, Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells., Mol. Pharmacol.
    Grenman et al., 1987, In vitro effects of tamoxifen on UM-SCC head and neck cancer cell lines: correlation with the estrogen and progesterone receptor content., Int. J. Cancer
    Osborne et al., 1997, Minor products of reaction of DNA with alpha-acetoxytamoxifen., Carcinogenesis

  • DTC: TAMOXIFEN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL83 ChEMBL Drug ID

    Drug Info:

    Publications:
    Scott SA et al., 2009, Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness., Nat Chem Biol
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Jain D et al., 2010, A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements., Bioorg Med Chem Lett

  • JAX-CKB: Tamoxifen

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Ribas et al., 2015, AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo., Mol. Cancer Ther.

  • PharmGKB: tamoxifen

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Narod SA et al., 2000, Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group., Lancet
    Metcalfe K et al., 2004, Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers., J Clin Oncol
    Gronwald J et al., 2006, Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update., Int J Cancer

  • CIViC: TAMOXIFEN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Stendahl et al., 2004, Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients., Br. J. Cancer
    Robinson et al., 2013, Activating ESR1 mutations in hormone-resistant metastatic breast cancer., Nat. Genet.
    Zheng et al., 2014, Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer., Oncogene

  • TTD: Tamoxifen

    • Version: 2020.06.01

    Alternate Names:
    D07KSG TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL83

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: TAMOXIFEN

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Tamoxifen

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: TAMOXIFEN

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21